AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRVO
  4. [Form 4] CervoMed Inc. Insider Trading Activity

[Form 4] CervoMed Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

CervoMed Inc. (CRVO) Form 4 filing discloses an initial equity grant to newly elected non-employee director Dr. Marwan Sabbagh. On 06/23/2025 he received a stock option for 8,100 common shares at an exercise price of $6.52 under the 2025 Equity Incentive Plan. The option vests in equal 1/12-increments on the last day of each month from 06/30/2025 through 05/31/2026, contingent on continued board service, and expires on 06/23/2035. No common shares were purchased or sold, and total derivative holdings now stand at 8,100 options. The transaction is routine director compensation with negligible dilution and no immediate impact on CervoMed鈥檚 financial position.

CervoMed Inc. (CRVO) ha presentato il modulo Form 4 che rivela una concessione iniziale di azioni al nuovo direttore non dipendente appena eletto, Dr. Marwan Sabbagh. Il 23/06/2025 ha ricevuto un opzione su azioni per 8.100 azioni ordinarie con un prezzo di esercizio di 6,52$ nell'ambito del Piano di Incentivi Azionari 2025. L'opzione matura in incrementi uguali di 1/12 l'ultimo giorno di ogni mese dal 30/06/2025 al 31/05/2026, a condizione che il servizio nel consiglio continui, e scade il 23/06/2035. Non sono state acquistate o vendute azioni ordinarie, e il totale delle partecipazioni derivate 猫 ora di 8.100 opzioni. La transazione rappresenta una normale compensazione per il direttore con una diluizione trascurabile e nessun impatto immediato sulla posizione finanziaria di CervoMed.

CervoMed Inc. (CRVO) ha presentado el formulario Form 4 que revela una concesi贸n inicial de acciones al director no ejecutivo reci茅n elegido, Dr. Marwan Sabbagh. El 23/06/2025 recibi贸 una opci贸n sobre 8.100 acciones ordinarias con un precio de ejercicio de $6.52 bajo el Plan de Incentivos de Capital 2025. La opci贸n se consolida en incrementos iguales de 1/12 el 煤ltimo d铆a de cada mes desde el 30/06/2025 hasta el 31/05/2026, condicionado a la continuidad en el servicio del consejo, y vence el 23/06/2035. No se compraron ni vendieron acciones ordinarias, y la tenencia total derivada ahora es de 8.100 opciones. La transacci贸n es una compensaci贸n rutinaria para el director con una diluci贸n insignificante y sin impacto inmediato en la posici贸n financiera de CervoMed.

CervoMed Inc. (CRVO)電� Form 4 鞝滌稖鞚� 韱淀暣 靸堧 靹犾瀯霅� 牍勳瀯鞗� 鞚挫偓 Dr. Marwan Sabbagh鞐愱矊 齑堦赴 欤检嫕 攵�鞐ゼ 瓿店皽頄堨姷雼堧嫟. 2025雲� 6鞗� 23鞚� 攴鸽姅 2025雲� 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 氤错喌欤� 8,100欤检棎 雽�頃� 鞀ろ啞 鞓奠厴鞚� 頄夓偓 臧�瓴� $6.52鞐� 氚涭晿鞀惦媹雼�. 鞚� 鞓奠厴鞚� 2025雲� 6鞗� 30鞚茧秬韯� 2026雲� 5鞗� 31鞚缄箤歆� 毵れ洈 毵愳澕鞐� 霃欖澕頃� 1/12鞌� 甓岆Μ臧� 氚滌儩頃橂┌, 鞚挫偓須� 靹滊箘鞀� 歆�靻嶌澊 臁瓣贝鞚措┌, 2035雲� 6鞗� 23鞚检棎 毵岆霅╇媹雼�. 氤错喌欤茧姅 毵れ垬 霕愲姅 毵る弰霅橃 鞎婌晿鞙茧┌, 齑� 韺岇儩 氤挫湢電� 順勳灛 8,100 鞓奠厴鞛呺媹雼�. 鞚� 瓯半灅電� 鞚挫偓 氤挫垬鞚� 鞚柬櫂鞙茧 頋劃 須臣臧� 氙鸽頃橂┌ CervoMed鞚� 鞛 靸來儨鞐� 歃夑皝鞝侅澑 鞓來枼鞚� 鞐嗢姷雼堧嫟.

CervoMed Inc. (CRVO) a d茅pos茅 le formulaire Form 4 r茅v茅lant une attribution initiale d鈥檃ctions 脿 un nouveau directeur non salari茅 r茅cemment 茅lu, Dr. Marwan Sabbagh. Le 23/06/2025, il a re莽u une option d鈥檃chat portant sur 8 100 actions ordinaires 脿 un prix d鈥檈xercice de 6,52 $ dans le cadre du Plan d鈥橧ncitation en Actions 2025. L鈥檕ption est acquise par tranches 茅gales de 1/12 le dernier jour de chaque mois du 30/06/2025 au 31/05/2026, sous r茅serve de la poursuite de son mandat au conseil, et expire le 23/06/2035. Aucune action ordinaire n鈥檃 茅t茅 achet茅e ou vendue, et le total des titres d茅riv茅s s鈥櫭﹍猫ve d茅sormais 脿 8 100 options. Cette op茅ration constitue une r茅mun茅ration habituelle du directeur avec une dilution n茅gligeable et sans impact imm茅diat sur la situation financi猫re de CervoMed.

CervoMed Inc. (CRVO) hat das Formular Form 4 eingereicht, das eine anf盲ngliche Aktienzuteilung an den neu gew盲hlten nicht gesch盲ftsf眉hrenden Direktor Dr. Marwan Sabbagh offenlegt. Am 23.06.2025 erhielt er eine Aktienoption 眉ber 8.100 Stammaktien zu einem Aus眉bungspreis von 6,52 $ im Rahmen des Equity Incentive Plans 2025. Die Option wird in gleichen 1/12-Schritten jeweils am letzten Tag eines Monats vom 30.06.2025 bis zum 31.05.2026 f盲llig, vorausgesetzt, er bleibt im Vorstand t盲tig, und l盲uft am 23.06.2035 ab. Es wurden keine Stammaktien gekauft oder verkauft, und der Gesamtbestand an Derivaten betr盲gt nun 8.100 Optionen. Die Transaktion stellt eine routinem盲脽ige Verg眉tung des Direktors dar, mit vernachl盲ssigbarer Verw盲sserung und ohne unmittelbare Auswirkung auf die finanzielle Lage von CervoMed.

Positive
  • None.
Negative
  • None.

Insights

TL;DR 鈥� Routine option grant aligns new director with shareholders; immaterial to capital structure, neutral for valuation.

The Form 4 records a standard non-employee director award: 8,100 options at $6.52, vesting monthly over one year. Such grants are customary for small-cap biotech boards and are designed to align governance incentives without requiring cash outlay. The size represents a tiny fraction of CervoMed鈥檚 outstanding shares, resulting in de minimis dilution and no earnings effect. Because no shares were bought or sold, insider sentiment cannot be inferred. Overall, the filing is administrative and should not materially influence investment decisions.

CervoMed Inc. (CRVO) ha presentato il modulo Form 4 che rivela una concessione iniziale di azioni al nuovo direttore non dipendente appena eletto, Dr. Marwan Sabbagh. Il 23/06/2025 ha ricevuto un opzione su azioni per 8.100 azioni ordinarie con un prezzo di esercizio di 6,52$ nell'ambito del Piano di Incentivi Azionari 2025. L'opzione matura in incrementi uguali di 1/12 l'ultimo giorno di ogni mese dal 30/06/2025 al 31/05/2026, a condizione che il servizio nel consiglio continui, e scade il 23/06/2035. Non sono state acquistate o vendute azioni ordinarie, e il totale delle partecipazioni derivate 猫 ora di 8.100 opzioni. La transazione rappresenta una normale compensazione per il direttore con una diluizione trascurabile e nessun impatto immediato sulla posizione finanziaria di CervoMed.

CervoMed Inc. (CRVO) ha presentado el formulario Form 4 que revela una concesi贸n inicial de acciones al director no ejecutivo reci茅n elegido, Dr. Marwan Sabbagh. El 23/06/2025 recibi贸 una opci贸n sobre 8.100 acciones ordinarias con un precio de ejercicio de $6.52 bajo el Plan de Incentivos de Capital 2025. La opci贸n se consolida en incrementos iguales de 1/12 el 煤ltimo d铆a de cada mes desde el 30/06/2025 hasta el 31/05/2026, condicionado a la continuidad en el servicio del consejo, y vence el 23/06/2035. No se compraron ni vendieron acciones ordinarias, y la tenencia total derivada ahora es de 8.100 opciones. La transacci贸n es una compensaci贸n rutinaria para el director con una diluci贸n insignificante y sin impacto inmediato en la posici贸n financiera de CervoMed.

CervoMed Inc. (CRVO)電� Form 4 鞝滌稖鞚� 韱淀暣 靸堧 靹犾瀯霅� 牍勳瀯鞗� 鞚挫偓 Dr. Marwan Sabbagh鞐愱矊 齑堦赴 欤检嫕 攵�鞐ゼ 瓿店皽頄堨姷雼堧嫟. 2025雲� 6鞗� 23鞚� 攴鸽姅 2025雲� 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 氤错喌欤� 8,100欤检棎 雽�頃� 鞀ろ啞 鞓奠厴鞚� 頄夓偓 臧�瓴� $6.52鞐� 氚涭晿鞀惦媹雼�. 鞚� 鞓奠厴鞚� 2025雲� 6鞗� 30鞚茧秬韯� 2026雲� 5鞗� 31鞚缄箤歆� 毵れ洈 毵愳澕鞐� 霃欖澕頃� 1/12鞌� 甓岆Μ臧� 氚滌儩頃橂┌, 鞚挫偓須� 靹滊箘鞀� 歆�靻嶌澊 臁瓣贝鞚措┌, 2035雲� 6鞗� 23鞚检棎 毵岆霅╇媹雼�. 氤错喌欤茧姅 毵れ垬 霕愲姅 毵る弰霅橃 鞎婌晿鞙茧┌, 齑� 韺岇儩 氤挫湢電� 順勳灛 8,100 鞓奠厴鞛呺媹雼�. 鞚� 瓯半灅電� 鞚挫偓 氤挫垬鞚� 鞚柬櫂鞙茧 頋劃 須臣臧� 氙鸽頃橂┌ CervoMed鞚� 鞛 靸來儨鞐� 歃夑皝鞝侅澑 鞓來枼鞚� 鞐嗢姷雼堧嫟.

CervoMed Inc. (CRVO) a d茅pos茅 le formulaire Form 4 r茅v茅lant une attribution initiale d鈥檃ctions 脿 un nouveau directeur non salari茅 r茅cemment 茅lu, Dr. Marwan Sabbagh. Le 23/06/2025, il a re莽u une option d鈥檃chat portant sur 8 100 actions ordinaires 脿 un prix d鈥檈xercice de 6,52 $ dans le cadre du Plan d鈥橧ncitation en Actions 2025. L鈥檕ption est acquise par tranches 茅gales de 1/12 le dernier jour de chaque mois du 30/06/2025 au 31/05/2026, sous r茅serve de la poursuite de son mandat au conseil, et expire le 23/06/2035. Aucune action ordinaire n鈥檃 茅t茅 achet茅e ou vendue, et le total des titres d茅riv茅s s鈥櫭﹍猫ve d茅sormais 脿 8 100 options. Cette op茅ration constitue une r茅mun茅ration habituelle du directeur avec une dilution n茅gligeable et sans impact imm茅diat sur la situation financi猫re de CervoMed.

CervoMed Inc. (CRVO) hat das Formular Form 4 eingereicht, das eine anf盲ngliche Aktienzuteilung an den neu gew盲hlten nicht gesch盲ftsf眉hrenden Direktor Dr. Marwan Sabbagh offenlegt. Am 23.06.2025 erhielt er eine Aktienoption 眉ber 8.100 Stammaktien zu einem Aus眉bungspreis von 6,52 $ im Rahmen des Equity Incentive Plans 2025. Die Option wird in gleichen 1/12-Schritten jeweils am letzten Tag eines Monats vom 30.06.2025 bis zum 31.05.2026 f盲llig, vorausgesetzt, er bleibt im Vorstand t盲tig, und l盲uft am 23.06.2035 ab. Es wurden keine Stammaktien gekauft oder verkauft, und der Gesamtbestand an Derivaten betr盲gt nun 8.100 Optionen. Die Transaktion stellt eine routinem盲脽ige Verg眉tung des Direktors dar, mit vernachl盲ssigbarer Verw盲sserung und ohne unmittelbare Auswirkung auf die finanzielle Lage von CervoMed.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sabbagh Marwan
(Last) (First) (Middle)
20 PARK PLAZA, SUITE 424
(Street)
BOSTON MA 02116
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $6.52 06/23/2025 A 8,100 (1) 06/23/2035 Common Stock 8,100 $0 8,100 D
Explanation of Responses:
1. On June 23, 2025, in connection with the Reporting Person's election to the Issuer's board of directors at its 2025 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,100 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2025, subject to the Reporting Person's continued service through the applicable vesting date.
/s/ William R. Elder, attorney-in-fact for the Reporting Person 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What insider transaction did CervoMed (CRVO) report on 06/23/2025?

A grant of 8,100 stock options to new director Dr. Marwan Sabbagh under the 2025 Equity Incentive Plan.

What is the exercise price and expiration date of the granted options?

The options carry a $6.52 exercise price and expire on 06/23/2035.

How does the vesting schedule work for these CRVO options?

They vest monthly in 1/12-increments on the last day of each month starting 06/30/2025, completing after one year.

Did the director buy or sell any CervoMed common stock?

No. The Form 4 shows only an option grant; no common shares were bought or sold.

Does this Form 4 filing materially affect CervoMed鈥檚 share count?

The 8,100-option grant represents immaterial dilution relative to the company鈥檚 outstanding shares.
Stock CRVO logo
CervoMed

NASDAQ:CRVO

CRVO Rankings

#6722 Ranked by Market Cap
N/A Ranked by Dividends

CRVO Latest News

Jul 28, 2025
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod鈥檚 Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
Jul 24, 2025
CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025
Jul 8, 2025
CervoMed Announces Late-Breaking Presentations at Alzheimer鈥檚 Association庐 International Congress 2025
Jun 10, 2025
CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization
May 12, 2025
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

CRVO Latest SEC Filings

Jul 28, 2025
[8-K] CervoMed Inc. Reports Material Event
Jun 25, 2025
[8-K] CervoMed Inc. Reports Material Event
Jun 25, 2025
[Form 4] CervoMed Inc. Insider Trading Activity
Jun 25, 2025
[Form 4] CervoMed Inc. Insider Trading Activity
Jun 25, 2025
[Form 4] CervoMed Inc. Insider Trading Activity

CRVO Stock Data

78.15M
5.79M
33.38%
17.22%
10.96%
Biotechnology
Pharmaceutical Preparations
United States
BOSTON